A
Amyloidosis Research Consortium
Pre-competitive pharma collaboration accelerating amyloidosis care
Amyloidosis Research Consortium
Pre-competitive pharma collaboration accelerating amyloidosis care
Overview
ASPIRE is a pre-competitive collaborative under the Amyloidosis Research Consortium that brings pharma and biotech partners together to tackle urgent amyloidosis care needs. It works through co-led working groups and regional networks that pool resources to develop shared, subsidized solutions, supported by AI-driven diagnostic pathways and patient journey mapping. The model relies on a neutral nonprofit backbone (ARC) to convene and align priorities across multiple companies, rather than competing on products. Its goal is to speed up diagnosis and care and reduce health disparities for people with amyloidosis.
Work here?Claim your company
Simplify's take
What believers are saying
- ARC says ASPIRE has one accepted manuscript and three more underway in 2026.
- The 2026 Forum expanded early-career training through Fellows and an Early Career Cohort.
- AstraZeneca and Ionis funded seven fellows, signaling continued external sponsorship.
What critics are saying
- ASPIRE depends on member dues; one sponsor exit can shrink programs immediately.
- ARC's CEO-centric model creates succession risk if Isabelle Lousada steps aside.
- Within 12-24 months, sponsor drift can hollow out ARC's convening power.
What makes Amyloidosis Research Consortium unique
- ARC convenes FDA, patients, and nine drugmakers through the 2021 ASPIRE pre-competitive forum.
- Its 2026 Forum drew 353 participants from 25 countries at FDA headquarters.
- Project ECHO and AI diagnostic reviews target community clinicians, not just specialist centers.
Help us improve and share your feedback! Did you find this helpful?